Nothing Special   »   [go: up one dir, main page]

MX2021011699A - Derivados de quinolina y su uso para el tratamiento del cancer. - Google Patents

Derivados de quinolina y su uso para el tratamiento del cancer.

Info

Publication number
MX2021011699A
MX2021011699A MX2021011699A MX2021011699A MX2021011699A MX 2021011699 A MX2021011699 A MX 2021011699A MX 2021011699 A MX2021011699 A MX 2021011699A MX 2021011699 A MX2021011699 A MX 2021011699A MX 2021011699 A MX2021011699 A MX 2021011699A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
quinoline derivatives
compounds
quinoline
Prior art date
Application number
MX2021011699A
Other languages
English (en)
Inventor
John Campbell
Darren Harvey
Eamon Comer
Kenneth Duncan
Alexis Cocozaki
Michael MUNCHHOF
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MX2021011699A publication Critical patent/MX2021011699A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación proporciona nuevos compuestos, composiciones que comprenden los compuestos y métodos de uso de los mismos.
MX2021011699A 2019-03-28 2020-03-27 Derivados de quinolina y su uso para el tratamiento del cancer. MX2021011699A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825507P 2019-03-28 2019-03-28
US201962952599P 2019-12-23 2019-12-23
PCT/US2020/025160 WO2020198567A1 (en) 2019-03-28 2020-03-27 Quinoline derivatives and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2021011699A true MX2021011699A (es) 2022-01-18

Family

ID=70334131

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011699A MX2021011699A (es) 2019-03-28 2020-03-27 Derivados de quinolina y su uso para el tratamiento del cancer.

Country Status (14)

Country Link
US (1) US20220144812A1 (es)
EP (1) EP3946623A1 (es)
JP (1) JP2022527279A (es)
KR (1) KR20210151849A (es)
CN (1) CN113891749A (es)
AU (1) AU2020244861A1 (es)
BR (1) BR112021019300A2 (es)
CA (1) CA3134826A1 (es)
CL (2) CL2021002501A1 (es)
CO (1) CO2021014351A2 (es)
IL (1) IL286649A (es)
MX (1) MX2021011699A (es)
SG (1) SG11202110591SA (es)
WO (1) WO2020198567A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240122941A1 (en) * 2020-12-25 2024-04-18 National Cancer Center Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0109122D0 (en) * 2001-04-11 2001-05-30 Smithkline Beecham Spa Novel compounds
CN101370782A (zh) * 2005-12-12 2009-02-18 阿斯利康(瑞典)有限公司 烷基磺酰胺喹啉
EP1981882A4 (en) * 2006-01-27 2009-11-18 Astrazeneca Ab QUINOLINES SUBSTITUTED BY AN AMIDE
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN101289460B (zh) * 2008-06-06 2011-09-14 山东大学 有机硼酸类化合物及其作为荧光探针的应用
CA2729988C (en) * 2008-07-10 2016-09-13 Pharma Ip General Incorporated Association Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
ES2898765T3 (es) * 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
MX2019001001A (es) 2016-07-25 2019-10-15 Epizyme Inc Terapia contra el cáncer relacionada con crebbp.
JP7203018B2 (ja) * 2016-09-26 2023-01-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド クロモボックスタンパク質阻害剤およびその使用
TWI808067B (zh) * 2016-12-19 2023-07-11 美商雅酶股份有限公司 作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法

Also Published As

Publication number Publication date
CA3134826A1 (en) 2020-10-01
EP3946623A1 (en) 2022-02-09
SG11202110591SA (en) 2021-10-28
CL2021002501A1 (es) 2022-06-17
BR112021019300A2 (pt) 2021-12-14
KR20210151849A (ko) 2021-12-14
IL286649A (en) 2021-10-31
WO2020198567A8 (en) 2020-11-19
CL2022003206A1 (es) 2023-07-07
CO2021014351A2 (es) 2022-01-17
AU2020244861A1 (en) 2021-11-18
WO2020198567A1 (en) 2020-10-01
US20220144812A1 (en) 2022-05-12
CN113891749A (zh) 2022-01-04
JP2022527279A (ja) 2022-06-01

Similar Documents

Publication Publication Date Title
PH12021500014A1 (en) Fused ring compounds
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
MX2020008404A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
NZ735998A (en) Heterocyclic compounds as lsd1 inhibitors
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
CR20210614A (es) Nuevos inhibidores de egfr
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2020005344A (es) Compuestos de pirazolopiridinona.